Insights

Sector analysis, case studies, and frameworks for understanding the European healthcare opportunity.

Sector AnalysisMarch 2026·8 min read

European HealthTech in 2026: The Opportunity in Numbers

France counts nearly 2,800 active HealthTech companies. They dedicate 64% of their spending to R&D — 75% in biotech alone. Yet only 20% raised capital in 2025, down from 37% the prior year. 41% report cash tensions. The average fundraising cycle stretches to 10 months. The science has never been stronger. Two-thirds of companies now use generative AI. 9% of biotech products are commercialized, up 3 points year-over-year.

Read full article

Case Studies

Real companies demonstrating the European healthcare opportunity.

Case StudyFrance · Biotech

Abivax

French biotech developing a first-in-class oral therapy for ulcerative colitis. Achieved Phase 3 success in July 2025. Stock surged approximately 500%. Raised $747.5M. NDA submission to FDA planned for H2 2026. The IBD market is projected to exceed $21 billion by 2032.

$747.5M

Capital Raised

~500%

Stock Surge

>$21B by 2032

Market Opportunity

Case StudyFrance · Medtech / Robotics

Wandercraft

French robotics company building self-balancing exoskeletons deployed in over 100 hospitals. Closed a $75M Series D in June 2025. Personal exoskeleton Eve launching in 2026. Revenue has grown 10x since the previous funding round.

$75M

Series D

100+

Hospital Deployments

10x

Revenue Growth

Coming Soon

Deep dives and frameworks currently in development.

Coming SoonFramework

How Value Is Created in Drug and Device Development

Coming SoonSector Analysis

AI in Healthcare: Where the Real Opportunity Lies

Coming SoonThesis

The Patent Cliff: Understanding the Structural M&A Thesis